Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00652340 · ClinicalTrials.gov registry record · Phase 2
APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer
A Phase 2 study of Recurrent Non-small Cell Lung Cancer, sponsored by Tragara Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT00652340: Completed Phase 2 study of Recurrent Non-small Cell Lung Cancer, sponsored by Tragara Pharmaceuticals.
NCT00652340 is a Phase 2 study of Recurrent Non-small Cell Lung Cancer that has completed, run by Tragara Pharmaceuticals. The registered enrollment target is 120 participants, below the 139-participant average among 15 other Recurrent Non-small Cell Lung Cancer trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00652340, a Phase 2 study of Recurrent Non-small Cell Lung Cancer, has completed, sponsored by Tragara Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will compare the anti-tumor efficacy of apricoxib and erlotinib with placebo and erlotinib as measured by time to disease progression to test the hypothesis that down regulation of COX-2 and EGFR pathways in patients with up-regulated COX-2 expression in tumor will have a clinical benefit compared with erlotinib alone.
Conditions Studied
Interventions
- DRUG apricoxib/erlotinib
- DRUG erlotinib/placebo
Study Locations (20)
California
- - Bakersfield
- - Los Angeles
- - Rancho Mirage
- - San Diego
- - San Dimas
- - Stockton
Florida
- - Lake North
- - Lakeland
- - Miami
Indiana
- - Kokomo
- - New Albany
Michigan
- - Ann Arbor
- - Jackson
Arizona
- - Tucson
Connecticut
- - Norwich
Georgia
- - Savannah
Illinois
- - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2008-04 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
What the finished NCT00652340 record still lists
NCT00652340 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 139-participant average among 15 other Recurrent Non-small Cell Lung Cancer trials with a reported enrollment target (14% lower).
The record links to 1 condition, with Recurrent Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which apricoxib/erlotinib is the first listed.
NCT00652340 names 20 study sites across 11 states, led by California, Florida, Indiana.
Frequently Asked Questions
What is clinical trial NCT00652340 about?
NCT00652340 is a clinical study titled "APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer". This study will compare the anti-tumor efficacy of apricoxib and erlotinib with placebo and erlotinib as measured by time to disease progression to test the hypothesis that down regulation of COX-2 and EGFR pathways in patients with up-regulated COX-2 expression in tumor will have a clinical benefit...
What is the current status of trial NCT00652340?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2008-04. Estimated completion is 2012-03.
What conditions does trial NCT00652340 study?
This clinical trial studies the following conditions: Recurrent Non-small Cell Lung Cancer.
What interventions are being tested in trial NCT00652340?
The interventions under investigation include: apricoxib/erlotinib (DRUG), erlotinib/placebo (DRUG).
Who is sponsoring clinical trial NCT00652340?
This trial is sponsored by Tragara Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00652340 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00652340's enrollment target sits among peer trials
120 4th of 15 higher than 12 of 15 other Recurrent Non-small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Non-small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
ACTIVE NOT RECRUITING · Phase 2
-
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer
COMPLETED · Phase 2
-
AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer
COMPLETED · Phase 2
-
A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer
COMPLETED · Phase 2
-
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
COMPLETED · Phase 2
-
CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia